299 related articles for article (PubMed ID: 24034306)
1. Melding regulatory, pharmaceutical industry, and U.S. payer perspectives on improving approaches to heterogeneity of treatment effect in research and practice.
Willke RJ; Crown W; Del Aguila M; Cziraky MJ; Khan ZM; Migliori R
Value Health; 2013; 16(6 Suppl):S10-5. PubMed ID: 24034306
[TBL] [Abstract][Full Text] [Related]
2. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
3. Regulation, reimbursement, and the long road of implementation of personalized medicine--a perspective from the United States.
Frueh FW
Value Health; 2013; 16(6 Suppl):S27-31. PubMed ID: 24034309
[TBL] [Abstract][Full Text] [Related]
4. Impact of Postapproval Evidence Generation on the Biopharmaceutical Industry.
Milne CP; Cohen JP; Felix A; Chakravarthy R
Clin Ther; 2015 Aug; 37(8):1852-8. PubMed ID: 26143223
[TBL] [Abstract][Full Text] [Related]
5. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001.
Acquadro C; Berzon R; Dubois D; Leidy NK; Marquis P; Revicki D; Rothman M;
Value Health; 2003; 6(5):522-31. PubMed ID: 14627058
[TBL] [Abstract][Full Text] [Related]
6. Improving Cardiovascular Drug and Device Development and Evidence Through Patient-Centered Research and Clinical Trials: A Call to Action From the Value in Healthcare Initiative's Partnering With Regulators Learning Collaborative.
Warner JJ; Crook HL; Whelan KM; Bleser WK; Roiland RA; Hamilton Lopez M; Saunders RS; Wang TY; Hernandez AF; McClellan MB; Califf RM; Brown N;
Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006606. PubMed ID: 32683985
[TBL] [Abstract][Full Text] [Related]
7. It is important to note that RWD will never replace the more traditional and more robust RCT data; however, the emerging trend is to incorporate data that are more generalizable. Introduction.
Mullins CD; Sanchez RJ
J Manag Care Pharm; 2011; 17(9 Suppl A):S03-4. PubMed ID: 22074667
[TBL] [Abstract][Full Text] [Related]
8. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
9. Patient-Focused Drug Development: A New Direction for Collaboration.
Perfetto EM; Burke L; Oehrlein EM; Epstein RS
Med Care; 2015 Jan; 53(1):9-17. PubMed ID: 25494232
[TBL] [Abstract][Full Text] [Related]
10. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
11. Outcomes research: collaboration among academic researchers, managed care organizations, and pharmaceutical manufacturers.
Kong SX; Wertheimer AI
Am J Manag Care; 1998 Jan; 4(1):28-34. PubMed ID: 10179904
[TBL] [Abstract][Full Text] [Related]
12. Communication about results of comparative effectiveness studies: a pharmaceutical industry view.
Perfetto EM; Bailey JE; Gans-Brangs KR; Romano SJ; Rosenthal NR; Willke RJ
Health Aff (Millwood); 2012 Oct; 31(10):2213-9. PubMed ID: 23048099
[TBL] [Abstract][Full Text] [Related]
13. The identification of benefit in medical intervention: an overview and suggestions for process.
Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
[TBL] [Abstract][Full Text] [Related]
14. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
Allen D; Rixson L
Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
[TBL] [Abstract][Full Text] [Related]
15. Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers: What can we learn from clinical research?
Eichler HG; Kong SX; Grégoire JP
Eur J Health Econ; 2006 Jun; 7(2):129-35. PubMed ID: 16485122
[TBL] [Abstract][Full Text] [Related]
16. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
17. What can be gained from increased early-stage interaction between regulators, payers and the pharmaceutical industry?
Wonder M
Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):465-7. PubMed ID: 24820934
[TBL] [Abstract][Full Text] [Related]
18. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
19. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.
Garrison LP; Carlson JJ; Bajaj PS; Towse A; Neumann PJ; Sullivan SD; Westrich K; Dubois RW
Am J Manag Care; 2015 Sep; 21(9):632-40. PubMed ID: 26618366
[TBL] [Abstract][Full Text] [Related]
20. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
